Interpretable Machine Learning Leverages Proteomics to Improve Cardiovascular Disease Risk Prediction and Biomarker Identification
Preprint
Abstract
Cardiovascular diseases (CVD), primarily coronary heart disease and stroke, rank amongst the leading causes of long-term disability and mortality. Providing accurate disease risk predictions and identifying genes associated with CVD are crucial for prevention, early intervention, and the development of novel medications. The recent availability of UK Biobank Proteomics data enables the investigation of the blood proteome and its association with a wide variety of diseases. We employed the Explainable Boosting Machine (EBM), an interpretable machine learning model, for CVD risk prediction. The EBM model using proteomics outperforms traditional clinical models with an AUROC of 0.767 and an AUPRC of 0.2405. Adding clinical features further improves the AUROC to 0.785 and the AUPRC to 0.2835. Our models demonstrate consistent performance across sexes and ethnicities. While most prior studies using proteomics data for disease prediction have primarily focused on maximizing the accuracy at the population level, our model provides additional enriched insights into individualized disease risk predictions and in-depth biological insights into biomarkers. Our analysis also uncovers nonlinear risks linked to varying feature values. We further corroborate our findings using statistical approaches and evidence from the literature. In conclusion, we present a highly accurate and explanatory framework for proteomics data analysis, offering comprehensive and in-depth molecular and clinical insights. Our findings support future approaches that prioritize individualized disease risk prediction and the identification of target genes for drug development.Keywords
All Related Versions
- Published version: Communications Medicine, 5 (1), 1.
This publication has 33 references indexed in Scilit:
- Plasma proteomic associations with genetics and health in the UK BiobankNature, 2023
- Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular EventsJAMA, 2023
- New Way to “SCORE” Risk: Updates on the ESC Scoring System and Incorporation into ESC Cardiovascular Prevention GuidelinesCurrent Cardiology Reports, 2022
- Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosisNature Reviews Cardiology, 2021
- GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic diseaseNature Reviews Endocrinology, 2021
- The changing landscape of atherosclerosisNature, 2021
- The UK Biobank resource with deep phenotyping and genomic dataNature, 2018
- Genomic atlas of the human plasma proteomeNature, 2018
- Anti-inflammatory therapeutics for the treatment of atherosclerosisNature Reviews Drug Discovery, 2011
- Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studiesThe Lancet, 2010